GlobeNewswire by notified

Azerion Holding B.V. and Azerion Group N.V. – Joint Press Release Publication of Azerion Holding B.V. Annual Report and Audited Financial Statements 2021

Share

Amsterdam, 23 May 2022 – Azerion has published the annual report and audited financial results for the full year 2021 of Azerion Holding B.V. (Annual Report). The Annual Report can be found at azerion.com/investors


Co-CEO Atilla Aytekin said: “Publishing our Annual Report is an important milestone for Azerion, following our listing at Euronext Amsterdam earlier in 2022. We look forward to continuing the engagements with the capital markets on the back of our Annual Report and our first quarter 2022 results announcement, planned for the end of May.”


The Annual Report includes updated financial statements as compared to the preliminary unaudited financial results full year 2021 published on 28 February 2022. The updates to the figures are mainly associated with acquisition accounting, following the completion of the acquisition audits, as well as the accounting treatment of the business combination with European FinTech IPO Company 1 (EFIC1) that was completed on 1 February 2022, tax and the refinancing of the Company’s bonds in 2021. 


In the income statement, operating profit was lower by approximately EUR 9.2 million as compared to the preliminary results 2021, while EBITDA increased by some EUR 1.8 million, mainly driven by higher depreciation and amortisation, as well as lower gains from currency translation effects. As a result, the loss after tax for the year was higher by approximately EUR 9.1 million, as compared to the preliminary results 2021.


The balance sheet’s assets increased by approximately EUR 15.8 million, mainly related to the completion of purchase price allocation of acquisitions. In addition, there was a reclassification of EUR 8.8 million associated with share appreciation rights related to acquisitions, from equity to other liabilities.


The cash flow statement was updated with reclassifications totalling some EUR 8.2 million comprising the pay-out of contingent consideration from cash flow from operating activities to cash flow from investing activities and the repayment of borrowings to former owners of acquired companies from cash flow from financing activities to cash flow from investing activities. In addition, there was a reclassification of approximately EUR 10.5 million associated with costs of early settlement of bonds from cash flow from operating activities to cash flow from financing activities.


The annual report and full year results of Azerion Holding B.V. cover the period from 1 January 2021 to 31 December 2021 and therefore relate to a period prior to the completion of the business combination between EFIC1 and Azerion Holding B.V. on 1 February 2022. The annual report and full year results 2021 for Azerion Holding B.V. do therefore not comprise any accounts or results of Azerion Group N.V. for 2021. The 2021 annual report and audited financial results for the full year 2021 of Azerion Group N.V., formerly known as EFIC1, can be found at azerion.com/investors


Contacts

Investor Relations
ir@azerion.com


Media
press@azerion.com



Disclaimer


This is a joint press release from Azerion Group N.V. and Azerion Holding B.V. This communication may contain information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.


The annual reports for the year 2021 for Azerion Holding B.V. and Azerion Group N.V. referenced in this press release may include forward looking statements. All statements other than statements of historical facts may be forward looking statements. Words and expressions such as believes, estimates, plans, projects, anticipates, expects, intends, may, will, should or other similar words or expressions are typically used to identify forward-looking statements. Forward-looking statements are subject to risks, uncertainties and other factors that are difficult to predict and that may cause the actual results of Azerion to differ materially from future results expressed or implied by such forward-looking statements. Any forward-looking statements reflect Azerion's current views and assumptions based on information currently available to Azerion's management. Forward looking statements speak only as of the date they are made, and Azerion does not assume any obligation to update such statements, except as required by law.


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 202224.6.2022 22:05:00 CEST | Press release

REPORT –ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcedthat its Annual General Meeting was held on Friday, June 24, 2022. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;Approval of the compens

Cleantech Building Materials: Results of Annual General Meeting24.6.2022 14:54:27 CEST | Press release

24 June 2022 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM ISIN: GBOOBD1LVD21 CLEANTECH BUILDING MATERIALS PLC Results of Annual General Meeting The Annual General Meeting (“AGM”) of Cleantech Building Materials plc (“CBM” or the “Company”) was held in London earlier today, 24 June 2022. Details of the resolutions to be considered at the AGM were published in the Notice of AGM which was posted to Shareholders on 1 June 2022 and is available on the Company’s website: www.cbm-plc.com. All resolutions as set out in the Notice of AGM were duly passed without discussion. In particular, the following resolutions were passed at the AGM. The AGM resolved to authorise the directors of the Company to allot shares and grant rights to subscribe for, or convert any security, into shares. The directors of the Company sought authority for the purposes of section 551 of the Companies Act to exercise all the powers of the Company to allot shares and grant ri

Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia24.6.2022 13:13:19 CEST | Press release

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower discontinuation rate due to adverse reactions (5.8% vs 21.1%) at 24 weeks1 CHMP recommendation comes after the approval of Scemblix by the US FDA and other countries’ regulatory authorities, potentially broadening access for more patients to Novartis transformative therapies in CML Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing au

Clariant’s shareholders approve all agenda items24.6.2022 11:30:00 CEST | Press release

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Integrated Report and Group Consolidated Financial Statements for fiscal year 2021 approvedGünter von Au reelected as Chairman of the Board of DirectorsThree new candidates join the Board of Directors: Ahmed Mohamed Alumar, Roberto César Gualdoni, Naveena ShastriConfirmed distribution of CHF 0.40 per shareKPMG confirmed as statutory auditor from 2022 MUTTENZ, JUNE 24, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today held its 27th Annual General Meeting (AGM) where the shareholders approved all agenda items and resolutions as proposed by the Board of Directors. The AGM was held virtually, where shareholders were able to exercise their rights exclusively via the independent proxy. Overall, 698'945'298 shares or around 70.19 % of the share capital of Clariant were represented. Günter von Au was reelected as Chairman of the Board of Directors. Additionally, three new members were voted to join by a large majo

Cool Company Ltd. – Mandatory Notification Of Trade24.6.2022 11:01:19 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 23 June 2022 acquired 7,865 shares in the Company at a price of NOK 90.274882 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,591,218 shares in the Company, equivalent to 38.97% of the Company’s shares. Please see the attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form